Lees Financial Statements From 2010 to 2024
| LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Check Lees Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lees Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Lees financial statements analysis is a perfect complement when working with Lees Pharmaceutical Valuation or Volatility modules.
Lees |
Lees Pharmaceutical Holdings Company Return On Asset Analysis
Lees Pharmaceutical's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lees Pharmaceutical Return On Asset | 0.0591 |
Most of Lees Pharmaceutical's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lees Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Lees Pharmaceutical Holdings has a Return On Asset of 0.0591. This is 100.68% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 142.21% lower than that of the firm.
Lees Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lees Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Lees Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lees Pharmaceutical competition to find correlations between indicators driving Lees Pharmaceutical's intrinsic value. More Info.Lees Pharmaceutical Holdings is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lees Pharmaceutical's earnings, one of the primary drivers of an investment's value.About Lees Pharmaceutical Financial Statements
Lees Pharmaceutical stakeholders use historical fundamental indicators, such as Lees Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lees Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lees Pharmaceutical's assets and liabilities are reflected in the revenues and expenses on Lees Pharmaceutical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lees Pharmaceutical Holdings. Please read more on our technical analysis and fundamental analysis pages.
Lees Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the Peoples Republic of China. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong. Lees Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1182 people.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |